Vaccine (Recombinant protein vaccine) · Immune activation, directed at Streptococcus pneumoniae capsular polysaccharides (serotypes 3, 6A, 7F, 8, 9N, 1 · developed by Merck Sharp & Dohme LLC
PCV21 (Capvaxive) is a 21-valent pneumococcal conjugate vaccine. Its polysaccharides from 21 Streptococcus pneumoniae serotypes are each conjugated to the CRM197 carrier protein, inducing active immunization against pneumococcal disease when given intramuscularly.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07284654 | Phase 3 | Pneumococcal Disease | Completed | PCVX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pneumococcal Disease